C-MYC DNA BINDING PARTNERS, MOTIFS, SCREENING ASSAYS, AND USES THEREOF

摘要

The development of a mammalian cell line that overexpresses Myc and the purification of significant quantities of c-Myc from these cells is described. Three types of c-Myc-driven protein oligomerization (or complex) formations are described: (1) homo-oligomer complexes (herein termed C1 complexes) formed by association of at least two peptides of c-Myc, (2) hetero-oligomer complexes (herein termed C2 complexes) formed by heterodimerization of at least two peptides, at least one of which is not the c-Myc peptide, and specifically hetero-oligomerization between c-Myc and a 26-29 kd factor, and (3) c-Myc-dependent hetero-oligomeric complexes (herein termed the C2' complex) formed in the presence of c-Myc, however such hetero-oligomeric proteins not containing any peptides which are c-Myc. The invention is further directed to a reliable and accurate method for objectively classifying compounds, including human pharmaceuticals, as inhibitors of c-Myc activity.